Claims for Patent: 9,896,499

Summary for Patent: 9,896,499

Title:	Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
Abstract:	The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.
Inventor(s):	Alitalo; Kari (Helsinki, FI), Lemstrom; Karl B. (Helsinki, FI), Nykanen; Antti I. (Helsinki, FI)
Assignee:	VEGENICS PTY LIMITED (South Yarra, Victoria, AU)
Application Number:	14/687,556
Patent Claims:	1. A method for inhibiting rejection of a vascularized tissue or vascularized organ transplant, or for inhibiting arteriosclerosis in a human allograft transplant recipient, comprising: administering to a human allograft transplant recipient a composition that comprises an endothelial growth factor inhibitor in an amount effective to inhibit rejection, or inhibit arteriosclerosis, wherein the endothelial growth factor inhibitor comprises a compound that inhibits stimulation of human VEGFR-3 by VEGF-C or inhibits stimulation of human VEGFR-3 by VEGF-D, and wherein the compound comprises a soluble human VEGFR-3 polypeptide. 2. The method of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, and wherein the composition is administered intravenously, intramuscularly, intraperitoneally, or perorally. 3. The method of claim 1, where the transplant is a vascularized tissue transplant. 4. The method of claim 1, wherein the transplant comprises a vascularized organ, or comprises an organ fragment capable of performing functions of the organ or capable of regenerating into the organ. 5. The method of claim 1, wherein the transplant comprises an organ selected from the group consisting of a heart, a lung, a liver, and a kidney. 6. The method of claim 1, wherein the composition is administered locally to the transplanted vascularized tissue or vascularized organ in the human allograft transplant recipient. 7. The method of claim 1, wherein the composition is administered systemically to the human allograft transplant recipient. 8. The method of claim 1, further comprising administering the composition to the organ or the organ donor before the transplant. 9. The method of claim 1, further comprising repeated administration of the composition to the human allograft transplant recipient. 10. The method of claim 1, wherein the composition is administered to the human allograft transplant recipient perioperatively, relative to the transplant operation. 11. The method of claim 1, wherein the composition is administered to the human allograft transplant recipient post-operatively, relative to the transplant operation. 12. The method of claim 1, comprising: screening the human allograft transplant recipient for symptoms of an acute rejection reaction; and administering the composition to the human allograft transplant recipient upon detection of symptoms of acute rejection, in an amount effective to inhibit the rejection. 13. The method of claim 1, wherein the polypeptide comprises a human VEGFR-3 extracellular domain polypeptide that binds VEGF-C or VEGF-D. 14. The method of claim 1, wherein the soluble VEGFR-3 polypeptide comprises the VEGFR-3 extracellular domain, or a fragment thereof sufficient to bind VEGF-C or VEGF-D and wherein the fragment consists of amino acid 138-226 of SEQ ID NO: 6. 15. The method of claim 1, wherein the soluble VEGFR-3 polypeptide comprises the first and second immunoglobulin-like domains of the VEGFR-3. 16. The method of claim 1, wherein the soluble VEGFR-3 polypeptide comprises the first, second, and third immunoglobulin-like domains of the VEGFR-3. 17. The method of claim 1, wherein the soluble VEGFR-3 polypeptide is fused to an immunoglobulin constant domain. 18. The method of claim 1, further comprising administering an immunosuppressive agent to the human allograft transplant recipient, wherein the immunosuppressive agent comprises at least one compound selected from the group consisting of: Tacrolimus, Mycophenolic acid, Prednisone, cyclosporine, Azathioprine, Basiliximab, Daclizumab, Muromonab-CD3, Mycophenolate Mofetil, Sirolimus, Methylprednisolone, Thymoglobulin, Rapamycin, and Interleukin-2 Receptor Antagonist. 19. The method of claim 18, further comprising administering an antibiotic or antifungal agent to the human allograft transplant recipient. 20. The method of claim 18, further comprising administering to a human donor organism a composition that comprises an endothelial growth factor inhibitor, prior to harvesting a vascularized tissue, or vascularized organ for transplantation into the human allograft transplant recipient. 21. The method of claim 1, further comprising administering an antibiotic or antifungal agent to the human allograft transplant recipient. 22. The method of claim 1, further comprising administering to a human donor organism a composition that comprises an endothelial growth factor inhibitor, prior to harvesting a vascularized tissue or vascularized organ for transplantation into the human allograft transplant recipient. 23. The method of claim 1, further comprising contacting a vascularized tissue or vascularized organ with a composition that comprises an endothelial growth factor inhibitor, prior to transplanting the vascularized tissue or vascularized organ into the human allograft transplant recipient. 24. A method for inhibiting rejection of a vascularized tissue or vascularized organ transplant, or for inhibiting arteriosclerosis in a human allograft transplant recipient, comprising: administering to a human allograft transplant recipient a composition that comprises an endothelial growth factor inhibitor in an amount effective to inhibit rejection, or inhibit arteriosclerosis, wherein the endothelial growth factor inhibitor comprises a compound that inhibits stimulation of human VEGFR-3 by VEGF-C or inhibits stimulation of human VEGFR-3 by VEGF-D, and wherein the compound comprises an amino acid sequence at least 95% identical to amino acids 138-226 of SEQ ID NO: 6, and that binds VEGF-C or VEGF-D. 25. The method of claim 24, wherein the inhibitor comprises an amino acid sequence at least 95% identical to amino acids 47-224 of SEQ ID NO: 6. 26. The method of claim 24, wherein the inhibitor comprises an amino acid sequence at least 95% identical to amino acids 47-314 of SEQ ID NO: 6. 27. The method of claim 24, wherein the inhibitor comprises an amino acid sequence at least 95% identical to amino acids 24-775 of SEQ ID NO: 6 or fragments thereof that bind VEGF-C. 28. A method for inhibiting rejection of a transplanted organ, or fragment thereof, the organ selected from the group consisting of a heart, a kidney, a lung, a liver, an intestine, a pancreas, skin, and bone, the method comprising: administering to a human transplant recipient a composition that comprises an endothelial growth factor inhibitor in an amount effective to inhibit rejection, wherein the endothelial growth factor inhibitor comprises a compound that inhibits stimulation of human VEGFR-3 by VEGF-C or inhibits stimulation of human VEGFR-3 by VEGF-D, and wherein the compound comprises a soluble human VEGFR-3 polypeptide. 29. The method of claim 1, wherein the composition is administered to the recipient for 1-90 days post-operatively, relative to the transplant operation. 30. The method of claim 1, wherein the composition is administered to the recipient for 1-60 days post-operatively, relative to the transplant operation. 31. The method of claim 1, wherein the composition is administered to the recipient for 1-30 days post-operatively, relative to the transplant operation. 32. The method of claim 1, wherein the composition is administered to the recipient for 1-15 days post-operatively, relative to the transplant operation. 33. The method of claim 1, further comprising administering to the recipient a composition that comprises at least one growth factor inhibitor selected from the group consisting of: inhibitors of VEGFR-1; inhibitors of VEGFR-2; inhibitors of PDGFR-alpha; and inhibitors of PDGFR-beta; wherein the combination of inhibitors are administered in amounts effective to inhibit rejection, or inhibit arteriosclerosis. 34. The method of claim 27, wherein the composition is administered to the recipient for 1-90 days post-operatively, relative to the transplant operation. 35. The method of claim 27, wherein the composition is administered to the recipient for 1-60 days post-operatively, relative to the transplant operation. 36. The method of claim 27, wherein the composition is administered to the recipient for 1-30 days post-operatively, relative to the transplant operation. 37. The method of claim 27, wherein the composition is administered to the recipient for 1-15 days post-operatively, relative to the transplant operation. 38. The method of claim 27, further comprising administering to the recipient a composition that comprises at least one growth factor inhibitor selected from the group consisting of: inhibitors of VEGFR-1; inhibitors of VEGFR-2; inhibitors of PDGFR-alpha; and inhibitors of PDGFR-beta; wherein the combination of inhibitors are administered in amounts effective to inhibit rejection, or inhibit arteriosclerosis.

Details for Patent 9,896,499

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2027-02-02
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2027-02-02
Genzyme Corporation	THYMOGLOBULIN	anti-thymocyte globulin (rabbit)	For Injection	103869	05/19/1999		2027-02-02
Biogen Inc.	ZINBRYTA	daclizumab	Injection	761029	05/27/2016		2027-02-02